AB-001 / Aubrak Therapeutics - LARVOL DELTA

INTERIM RESULTS FROM THE PHASE I IBC -01-01 STUDY: THE FIRST IMMUNE CHECKPOINT INHIBITOR THERAPY IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE (ADPD 2025) - "IBC -01-01 is a Phase I clinical study investigating the safety, tolerability, and preliminary efficacy of IBC -Ab001, a no vel immunomodulatory agent designed to harness peripheral immunity by targeting the inhibitory immune checkpoint PD -L1 in patients with early AD. IBC-01-01 adopts an innovative approach in AD treatment by targeting an immune checkpoint inhibitor for the fir st time in dementia therapy. This first -of-its-kind treatment represents a unique approach to targeting AD by leveraging the physiological role of the immune system in brain repair."

Checkpoint inhibition • Clinical • IO biomarker • P1 data • Alzheimer's Disease • CNS Disorders • Dementia • Inflammation • Oncology • APOE

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. (PubMed, J Nucl Med) - "γ-camera imaging of AB001 was feasible, even at a microdose, and demonstrated metastatic targeting, albeit for only 1 lesion. The promising biodistribution and clearance encourage further clinical investigation."

Journal • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1